FOSL1 and glioblastoma: Although FOSL1/FRA-1 pharmacological inhibition is difficult to achieve due to its enzymatic activity, a gene therapy approach targeting FOSL1/FRA-1 expression through CRISPR/Cas9 or PROTAC, for instance, could constitute attractive alternatives to treat mesenchymal GBM patients.